Adjuvant Chemotherapy and Survival in MSI-High Stages II and III Colon Cancer: Impact of Histopathologic Risk Stratification
A patient's MSI-H status alone should not preclude the use of ACT in colon cancer. This study demonstrated a significant survival benefit of ACT for both high-risk stage II and stage III MSI-H patients. Histopathologic risk stratification should guide treatment decisions for stage II MSI-H colon cancer, and ACT may be recommended for patients with multiple adverse pathologic features.
Authors
- Salih Nafiz Karahan (ORCID: https://orcid.org/0000-0002-3610-7390)
- Mustafa Oruç (ORCID: https://orcid.org/0000-0002-7918-1689)
- Volkan Özben (ORCID: https://orcid.org/0000-0002-9620-5080)
- Çiğdem Benlice (ORCID: https://orcid.org/0000-0002-5211-1779)
- Emre Görgün (ORCID: https://orcid.org/0000-0001-7725-3522)
- Bilgi Baca (ORCID: https://orcid.org/0000-0003-1704-2533)
- Metincan Erkaya (ORCID: https://orcid.org/0000-0002-4707-6059)
Institutions
- Cleveland Clinic (US)
- Acıbadem University (TR)
- Kent Hastanesi (TR)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2025-10-07
- DOI
- https://doi.org/10.1245/s10434-025-18285-7
- Citations
- 1
- Primary Topic
- Colorectal Cancer Surgical Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.05